Shanghai Pharmaceuticals (SHA:601607, HKG:2607) reported 3.5 billion yuan in profit attributable to equity holders for the first half, compared with 4.46 billion yuan a year ago, a Thursday bourse filing showed.
EPS moved to 0.95 yuan from 1.20 yuan year over year.
For the six months ended June 30, operating revenue was 147.5 billion yuan, versus 141.6 billion yuan previously, the pharmaceutical company said.
The company proposed an interim dividend of 1 yuan per 10 shares for the period.